Cargando…
Generation and manipulation of human iPSC-derived platelets
The discovery of iPSCs has led to the ex vivo production of differentiated cells for regenerative medicine. In the case of transfusion products, the derivation of platelets from iPSCs is expected to complement our current blood-donor supplied transfusion system through donor-independent production w...
Autores principales: | Sugimoto, Naoshi, Eto, Koji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804213/ https://www.ncbi.nlm.nih.gov/pubmed/33439272 http://dx.doi.org/10.1007/s00018-020-03749-8 |
Ejemplares similares
-
Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets
por: Chen, Si Jing, et al.
Publicado: (2022) -
Ex Vivo Production of Platelets From iPSCs: The iPLAT1 Study and Beyond
por: Sugimoto, Naoshi, et al.
Publicado: (2023) -
Ex vivo generation of platelet products from human iPS cells
por: Nakamura, Sou, et al.
Publicado: (2020) -
Production and nonclinical evaluation of an autologous iPSC–derived platelet product for the iPLAT1 clinical trial
por: Sugimoto, Naoshi, et al.
Publicado: (2022) -
iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity
por: Suzuki, Daisuke, et al.
Publicado: (2019)